Progress in global rollout of new multidrug-resistant tuberculosis treatments

K. Held, S. McAnaw, C. Y. Chiang, A. Trebucq, C. R. Horsburgh

研究成果: 雜誌貢獻文章同行評審

摘要

SETTING: The global multidrug-resistant tuberculosis (MDR-TB) epidemic has grown over the past decade and continues to be difficult to manage. In response, new drugs and treatment regimens have been recommended. OBJECTIVE : In 2017 and again in 2018, the International Union Against Tuberculosis and Lung Disease (The Union) drug-resistant (DR) TB Working Group collaborated with RESIST-TB to implement an internet survey to members of The Union around the world to assess access to these new treatment strategies. DESIGN: A nine-question survey was developed using SurveyMonkeyw. The survey was open for participation to all members of The Union registered under the TB Section. Two reminders were sent during each survey. The responses were analyzed taking into account the WHO Region to which the respondent belonged. RESULT S : The 2018 survey showed a global increase in implementation of the shorter (9-month) MDR-TB regimen (from 33% to 56% of respondents, P< 0.001) and an increase in the use of bedaquiline and/or delamanid (from 25% to 41% of respondents, P < 0.001) compared to 2017. There were substantial variations in roll-out between WHO regions. CONCLUS ION: These results demonstrate improvement in global implementation of the new treatment strategies over a 1-year period.
原文英語
頁(從 - 到)996-999
頁數4
期刊International Journal of Tuberculosis and Lung Disease
23
發行號9
DOIs
出版狀態已發佈 - 九月 1 2019

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Infectious Diseases

指紋 深入研究「Progress in global rollout of new multidrug-resistant tuberculosis treatments」主題。共同形成了獨特的指紋。

引用此